Author

E. M. Westerhout

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1

Frequent Co-Authors

J. Koster· 2 shared R. Versteeg· 2 shared A. Alchahin· 1 shared A. Chan· 1 shared A. Lakeman· 1 shared B. Embaie· 1 shared C. Dyberg· 1 shared C. Tummler· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Koster

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma

T. K. Olsen, C. Dyberg, B. Embaie, A. Alchahin, J. Milosevic, J. Otte, C. Tummler, I. H. Myrberg, E. M. Westerhout, J. Koster, R. Versteeg, P. Kogner, J. I. Johnsen, D. B. Sykes, N. Baryawno

This study identifies DHODH as a prognostic marker and therapeutic target in neuroblastoma, showing its inhibition improves survival in preclinical models and suggests combination therapy with temozolomide.

bioRxiv · Sep 25, 2021Cancer Biology

An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite

T. van Groningen, C. U. Niklasson, A. Chan, N. Akogul, E. M. Westerhout, K. von Stedingk, M. Hamdi, L. J. Valentijn, S. Mohlin, P. Stroeken, N. E. Hasselt, F. Haneveld, A. Lakeman, D. A. Zwijnenburg, P. van Sluis, , J. van Nes

The paper identifies an immature neuroblastoma subset that synthesizes retinoic acid and is resistant to it, potentially contributing to therapy-resistant relapses.

bioRxiv · May 18, 2021 · PreprintCancer Biology